Table 4.
Univariate and multiple variate analysis of multi-RFA vs. hepatectomy.
| Variable | Univariate | Multiple Variate | ||
|---|---|---|---|---|
| Risk Ratio (95% CI) | p-Value | Risk Ratio (95% CI) | p-Value | |
| Hepatectomy versus multi-RFA | 1.284 (0.649–2.539) | 0.473 | ||
| Age (≥65) | 1.859 (0.972–3.558) | 0.061 | ||
| Gender (male) | 0.754 (0.397–1.432) | 0.388 | ||
| ECOG (yes) | 3.349 (1.271–8.820) | 0.014 * | 0.698 (0.087–5.594) | 0.735 |
| Comorbidity (yes) | 1.955 (1.012–3.779) | 0.046 * | 1.327 (0.500–3.520) | 0.570 |
| Tumor location | 1.707 (0.876–3.326) | 0.116 | ||
| High tumor grade | 39.844 (6.554–242.227) | <0.001 * | N/A | |
| T (T4) | 0.882 (0.118–6.587) | 0.902 | ||
| N (positive) | 2.064 (0.998–4.271) | 0.051 | ||
| M (positive) | 4.753 (1.755–12.874) | 0.002 * | 14.45 (3.49–59.84) | <0.001 * |
| EGFR (mutant) | 0.231 (0.024–2.259) | 0.208 | ||
| KRAS (mutant) | 1.003 (0.467–2.156) | 0.993 | ||
| NRAS (mutant) | 12.649 (0.776–206.139) | 0.075 | ||
| BRAF (mutant) | 20.50 (1.81–231.97) | 0.015 * | 272.2 (6.78–10,920) | 0.003 * |
| Bilateral metastasis | 1.373 (0.533–3.538) | 0.512 | ||
| EHD at CRLM | 1.699 (0.882–3.273) | 0.113 | ||
| Neoadjuvant chemotherapy | 0.963 (0.294–3.153) | 0.951 | ||
| Anti-VEGF (yes) | 0.892 (0.470–1.693) | 0.726 | ||
| Anti-EGFR (yes) | 0.711 (0.324–1.563) | 0.396 | ||
| TACE/Y90 (yes) | 0.882 (0.310–2.508) | 0.814 | ||
| RT (yes) | 2.871 (1.475–5.589) | 0.002 * | 4.834 (1.610–14.512) | 0.005 * |
| Initial no (≥4) | 0.047 (0.000–1194.315) | 0.556 | ||
| Largest diameter (≥30 mm) | 1.274 (0.669–2.425) | 0.461 | ||
| Total diameter (≥50 mm) | 1.441 (0.343–6.056) | 0.618 | ||
| CEA (≥30 ng/mL) | 1.393 (0.183–10.582) | 0.749 | ||
| CA19-9 (≥100 U/mL) | 2.118 (0.463–9.688) | 0.333 | ||
| CEA at CRLM (≥30 ng/mL) | 1.311 (0.528–3.254) | 0.559 | ||
| CA19-9 at CRLM (≥100 U/mL) | 2.390 (0.847–6.746) | 0.100 | ||
| Time to CRLM (> 730 days) | 0.949 (0.481–1.875) | 0.880 | ||
* p < 0.05.